search
Back to results

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Primary Purpose

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Disitamab Vedotin Tislelizumab
Disitamab Vedotin
Sponsored by
Tianjin Medical University Second Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma focused on measuring Disitamab Vedotin, Tislelizumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years;
  2. Urothelial carcinoma with Her2 IHC 2+ or 3+;
  3. High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:

    a. T1 b. High-grade Ta c.Carcinoma in situ(CIS);

  4. Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
  5. Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;)
  6. Organ function level must meet or under the support treatment meet the following requirements:

    • Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 100x10^9/L, hemoglobin >= 9.0 g/dl;
    • Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN(patient with metastatic liver cancer:aminotransferase <=5.0 ULN);
    • Renal function: creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 50 ml/min;
  7. The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;

Exclusion Criteria:

  1. Active, known or suspected autoimmune diseases;
  2. History of primary immunodeficiency;
  3. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
  4. Pregnant or lactating female patients;
  5. Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
  6. Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose);
  7. Known or suspected allergy to disitamab vedotin or tislelizumab;
  8. Have a clear history of active tuberculosis;
  9. Participating in other clinical researchers;
  10. Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
  11. Uncontrolled concurrent diseases, including but not limited to:

    • HIV infected (HIV antibody positive);
    • Severe infection in active stage or poorly controlled;
    • Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]);
    • Patients with active bleeding or new thrombotic disease

Sites / Locations

  • Tianjin Medical University Second HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Disitamab Vedotin and Tislelizumab

Disitamab Vedotin

Arm Description

Disitamab Vedotin 120mg IV on day 1 in combination with Tislelizumab 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.

Disitamab Vedotin 120mg IV on day 1 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.

Outcomes

Primary Outcome Measures

Complete Response (CR) Rate

Secondary Outcome Measures

Progress Free Survival(PFS)
Recurrence Free Survival(RFS)
Cystectomy-Free Survival (CFS)
defined from D1 of treatment until cystectomy
Duration of Response (DOR)
Event-Free Survival(EFS)
defined from D1 of treatment until the time of any events,included progressive disease,discontinue treatment for any cause or death
Number of adverse events and severity by grade (CTCAE)
Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0, as well as a patient questionnaire derived from the Patient Reported Outcomes (PRO)-CTCAE and Patient Reported Outcomes Measurement Information System (PROMIS).
Her2 status
PD-1 expression status

Full Information

First Posted
August 9, 2022
Last Updated
August 9, 2022
Sponsor
Tianjin Medical University Second Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05495724
Brief Title
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Official Title
An Open Label, Phase 2 Study of Disitamab Vedotin Combined With Tislelizumab for Patients With Her2 Overexpressing (IHC2+ or 3+) High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 23, 2021 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
July 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tianjin Medical University Second Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a phase II study to determine the safety and efficacy of Disitamab Vedotin when given in combination with Tislelizumab as treatment for patients with Her2 overexpressing high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with Disitamab Vedotin in combination with tislelizumab every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Keywords
Disitamab Vedotin, Tislelizumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
176 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Disitamab Vedotin and Tislelizumab
Arm Type
Experimental
Arm Description
Disitamab Vedotin 120mg IV on day 1 in combination with Tislelizumab 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
Arm Title
Disitamab Vedotin
Arm Type
Other
Arm Description
Disitamab Vedotin 120mg IV on day 1 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
Intervention Type
Drug
Intervention Name(s)
Disitamab Vedotin Tislelizumab
Other Intervention Name(s)
KEYNOTE-057
Intervention Description
Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Intervention Type
Drug
Intervention Name(s)
Disitamab Vedotin
Intervention Description
Disitamab Vedotin
Primary Outcome Measure Information:
Title
Complete Response (CR) Rate
Time Frame
At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of disitamab vedotin)
Secondary Outcome Measure Information:
Title
Progress Free Survival(PFS)
Time Frame
up to 3 years
Title
Recurrence Free Survival(RFS)
Time Frame
up to 3 years
Title
Cystectomy-Free Survival (CFS)
Description
defined from D1 of treatment until cystectomy
Time Frame
up to 3 years
Title
Duration of Response (DOR)
Time Frame
up to 3 years
Title
Event-Free Survival(EFS)
Description
defined from D1 of treatment until the time of any events,included progressive disease,discontinue treatment for any cause or death
Time Frame
up to 3 years
Title
Number of adverse events and severity by grade (CTCAE)
Description
Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0, as well as a patient questionnaire derived from the Patient Reported Outcomes (PRO)-CTCAE and Patient Reported Outcomes Measurement Information System (PROMIS).
Time Frame
12 weeks of treatment plus 30 days for toxicity followup
Title
Her2 status
Time Frame
up to 3 years
Title
PD-1 expression status
Time Frame
up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years; Urothelial carcinoma with Her2 IHC 2+ or 3+; High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following: a. T1 b. High-grade Ta c.Carcinoma in situ(CIS); Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist; Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;) Organ function level must meet or under the support treatment meet the following requirements: Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 100x10^9/L, hemoglobin >= 9.0 g/dl; Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN(patient with metastatic liver cancer:aminotransferase <=5.0 ULN); Renal function: creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 50 ml/min; The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up; Exclusion Criteria: Active, known or suspected autoimmune diseases; History of primary immunodeficiency; Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; Pregnant or lactating female patients; Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions; Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose); Known or suspected allergy to disitamab vedotin or tislelizumab; Have a clear history of active tuberculosis; Participating in other clinical researchers; Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures; Uncontrolled concurrent diseases, including but not limited to: HIV infected (HIV antibody positive); Severe infection in active stage or poorly controlled; Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]); Patients with active bleeding or new thrombotic disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hailong Hu
Phone
+86-13662096232
Email
hhllove2004@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hailong Hu
Organizational Affiliation
Tianjin Medical University Second Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tianjin Medical University Second Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300211
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hailong Hu
Phone
+86-13662096232
Email
hhllove2004@163.com
First Name & Middle Initial & Last Name & Degree
Hailong Hu, MD,PhD

12. IPD Sharing Statement

Learn more about this trial

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

We'll reach out to this number within 24 hrs